BrainsWay (BWAY) to Release Earnings on Tuesday

BrainsWay (NASDAQ:BWAYGet Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect BrainsWay to post earnings of $0.01 per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

BrainsWay (NASDAQ:BWAYGet Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.04 earnings per share for the quarter. BrainsWay had a net margin of 1.67% and a return on equity of 1.45%. The business had revenue of $10.01 million for the quarter, compared to the consensus estimate of $9.40 million. During the same period last year, the company posted ($0.05) EPS. On average, analysts expect BrainsWay to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BrainsWay Stock Performance

Shares of BWAY stock remained flat at $10.32 on Tuesday. 20,364 shares of the stock traded hands, compared to its average volume of 94,862. BrainsWay has a one year low of $3.78 and a one year high of $10.61. The company has a fifty day simple moving average of $8.85 and a two-hundred day simple moving average of $7.20. The firm has a market cap of $172.14 million, a price-to-earnings ratio of 206.44 and a beta of 1.25.

Wall Street Analysts Forecast Growth

BWAY has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of BrainsWay in a report on Monday, October 21st. Northland Securities lifted their price objective on shares of BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a report on Thursday, October 3rd.

Get Our Latest Research Report on BWAY

BrainsWay Company Profile

(Get Free Report)

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

Featured Stories

Earnings History for BrainsWay (NASDAQ:BWAY)

Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.